DUBLIN--(BUSINESS WIRE)--The "U.S. Office Based Labs Market Size, Share & Trends Analysis Report By Modality (Single Specialty, Multi-Specialty), By Service, By Specialist (Vascular Surgeons, Interventional Cardiologists), And Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.
The U.S. office-based labs market size is expected to reach USD 15.3 billion by 2026, registering an 8.7% CAGR during the forecast period.
Increasing prevalence of target diseases and rising preference for minimally invasive procedures in outpatient settings are major factors driving demand for office-based labs (OBL) in U.S. High prevalence of risk factors such as smoking, high blood pressure, diabetes, and high cholesterol, in combination with rising geriatric population, are expected to increase the incidence of peripheral artery diseases (PAD). The resultant surge in number of procedures performed for their treatment is anticipated to fuel the OBL market during the forecast period.
More than 250 million people worldwide suffer from peripheral artery diseases and their prevalence increased by 24% between 2000 and 2010; the trend is expected to continue over the coming years. Low-income countries witnessed a 29% growth in number of individuals suffering from PADs in the past decade, while high-income countries witnessed a growth of 13%. PADs increase the risk of stroke and heart attack and often lead to ischemic amputations. According to an estimation, 150,000 cases of ischemic amputations are recorded every year in U.S. alone.
Many service providers are available in U.S., such as National Cardiovascular Partners and Envision Healthcare and Surgery Partners, providing services related to office-based surgery to patients at an affordable cost.
Further key findings from the study suggest:
- Single specialty OBLs spearheaded the market in 2018, whereas hybrid office-based labs are anticipated to witness high growth during the forecast period. Single-specialty labs offer more patient-centric treatments while hybrid models offer more profitability with multiple facilities under one roof.
- Peripheral vascular interventions (PVI) dominated the U.S. office-based labs market by service owing to high prevalence of arteriosclerosis in the country. A large number of balloon angioplasty and stenting procedures being performed in patients with blocked arteries and veins has also aided segment growth.
- Vascular surgeons are leading service providers in OBLs and held a major share in 2018 in terms of specialist. This is attributed to the rising burden of vascular diseases in the country. All the major vascular surgeries such as aortic, mesenteric, renal, subclavian, iliofemoral, tibial, and pedal are being performed by vascular surgeons in office settings.
- In U.S. almost 70% of surgical procedures are performed in outpatient settings, out of which, around 25% are performed in a physician's office.
- Key suppliers of vascular intervention devices include Abbott; Medtronic; Boston Scientific; and Cardiovascular System, Inc.
In June 2017, Philips acquired CardioProlific Inc.-a U.S.-based privately held company involved in the development of catheter-based thrombectomy procedures for management of peripheral vascular disease. This helped strengthen its pipeline of catheter-based therapy devices that can be used for inpatient and outpatient facilities.
Key Topics Covered
Chapter 1 Methodology & Scope
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 U.S. Office-based Labs (OBLs) Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 Penetration & Growth Prospect Mapping
3.2.1 Penetration & Growth Prospect Mapping Analysis
3.3 Regulatory Framework & Reimbursement Scenario
3.3.1 Regulatory Framework
3.3.2 Reimbursement Scenario
3.4 Market Dynamics
3.4.1 Market Driver Analysis
220.127.116.11 Increasing prevalence of target diseases
18.104.22.168 Preference to minimally invasive procedures
3.4.2 Market Restraint Analysis
22.214.171.124 High risk option for severe cases
126.96.36.199 Lack of technical training for the MIS procedure
3.4.3 Industry Opportunities
188.8.131.52 Approval of endovascular procedures in Office-based labs
184.108.40.206 Flexibility for physicians to convert to OBLs
3.5 Business Environment Analysis Tools
3.5.1 Porter's Five Forces Analysis
3.5.2 PESTEL Analysis
Chapter 4 U.S. Office-based Labs (OBLs) Market: Modality Analysis
4.1 U.S. Office-based Labs (OBLs) Modality Market Share Analysis, 2018 & 2026
4.2 U.S. Office-based Labs (OBLs) Modality Market: Segment Dashboard:
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Modality Segment
4.3.1 Single Specialty Labs
4.3.2 Multi-Specialty Labs
4.3.3 Hybrid Labs
Chapter 5 U.S. Office-based Labs (OBLs) Market: Service Analysis
5.1 U.S. Office-based Labs (OBLs) Market Services Market Share Analysis, 2018 & 2026
5.2 U.S. Office-based Labs (OBLs) Market Services Market: Segment Dashboard
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Service
5.3.1 Peripheral Vascular Intervention
5.3.2 Endovascular Interventions
5.3.4 Interventional Radiology
5.3.6 Other Services
Chapter 6 U.S. Office-based Labs (OBLs) Market: Specialist Analysis
6.1 U.S. Office-based Labs (OBLs) Market Specialists Market Share Analysis, 2018 & 2026
6.2 U.S. Office-based Labs (OBLs) Market Specialists Market: Segment Dashboard
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Specialist
6.3.1 Vascular Surgeons
6.3.2 Interventional Cardiologists
6.3.3 Interventional Radiologists
6.3.4 Other Specialists
Chapter 7 U.S. Office-based Labs (OBLs) Market: Regional Analysis
7.1 U.S. Office-based Labs (OBLs) Market, 2015 - 2026 (USD Million)
Chapter 8 Competitive Analysis
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.2 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players
8.3 Vendor Landscape
8.3.2 Marketing & Promotions
8.4.1 Market Position Analysis: Imaging Devices Manufacturer
8.4.2 Market Position Analysis: Vascular Intervention Devices
8.5 Service Providers
8.5.1 Market Position Analysis
8.6 Suppliers Company Profiles
8.6.1 Philips Healthcare
220.127.116.11 Company overview
18.104.22.168 Financial performance
22.214.171.124 Product benchmarking
126.96.36.199 Strategic initiatives
188.8.131.52 SWOT analysis
8.6.2 GE Healthcare
8.6.3 Siemens Healthineers
8.6.5 Boston Scientific Corporation
8.6.7 Cardiovascular Systems Inc.
8.7 Service Providers Company Profiles
8.7.1 Envision Healthcare
8.7.2 Surgery Care Affiliates (SCA)
8.7.3 Tenet Healthcare Corporation
8.7.4 National Cardiovascular Partners L.P.
8.7.5 Surgery Partners
8.7.6 Cardiovascular Coalition
For more information about this report visit https://www.researchandmarkets.com/r/attgjc